AXL-CAR T cells alone only moderately suppressed tumour growth, but their combination with MWA enabled effective AXL-CAR T cell therapy that reduced HA, increased vascularisation, decreased IFP, and alleviated hypoxia. The gene discussed is AXL; the disease is neoplasm.